Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001214659-25-010763
Filing Date
2025-07-22
Accepted
2025-07-22 16:30:42
Documents
74
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 u7925110k.htm   iXBRL 10-K 1665839
2 EXHIBIT 4.4 ex4_4.htm EX-4.4 7163
3 EXHIBIT 19.1 ex19_1.htm EX-19.1 50256
4 EXHIBIT 23.1 ex23_1.htm EX-23.1 2865
5 EXHIBIT 31.1 ex31_1.htm EX-31.1 8384
6 EXHIBIT 31.2 ex31_2.htm EX-31.2 8357
7 EXHIBIT 32.1 ex32_1.htm EX-32.1 5384
13 GRAPHIC patientpopulation.jpg GRAPHIC 126431
14 GRAPHIC productcandidate.jpg GRAPHIC 103679
15 GRAPHIC titleofpatient.jpg GRAPHIC 94482
  Complete submission text file 0001214659-25-010763.txt   6986722

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE alzm-20250430.xsd EX-101.SCH 52944
9 XBRL CALCULATION FILE alzm-20250430_cal.xml EX-101.CAL 40836
10 XBRL DEFINITION FILE alzm-20250430_def.xml EX-101.DEF 191413
11 XBRL LABEL FILE alzm-20250430_lab.xml EX-101.LAB 347196
12 XBRL PRESENTATION FILE alzm-20250430_pre.xml EX-101.PRE 296087
76 EXTRACTED XBRL INSTANCE DOCUMENT u7925110k_htm.xml XML 788890
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-K | Act: 34 | File No.: 001-40483 | Film No.: 251140622
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)